Who owns Biomarin Pharma Inc convertible/?
- CUSIP Number: 09061gah4
Tip: Access positions for across all investors
Analyze quarterly positions in Biomarin Pharma Inc convertible/ with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Biomarin Pharma Inc convertible/ stock
Who bought or sold Biomarin Pharma Inc convertible/ this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| OZ Management | 35M | $35M | 100% | Dec 2023 |
|
| Millennium Management | 25M | $25M | 100% | Dec 2023 |
|
| Citigroup | 25M | $25M | -18% | Dec 2023 |
|
| Aviva | 25M | $25M | 0% | Dec 2023 |
|
| Two Sigma Investments | 20M | $20M | 480% | Dec 2023 |
|
| Calamos Advisors | 20M | $20M | -2% | Dec 2023 |
|
| Partner Fund Management | 15M | $15M | 0% | Dec 2023 |
|
| Bank of America Corporation | 13M | $13M | 6% | Dec 2023 |
|
| Lord, Abbett & Co | 12M | $12M | 100% | Dec 2023 |
|
| Sunrise Partners Limited Partnership | 11M | $11M | 9% | Dec 2023 |
|
| Centiva Capital | 11M | $10M | 5% | Dec 2023 |
|
| Jpmorgan Chase & Co | 10M | $10M | -20% | Dec 2023 |
|
| RWC Asset Management | 10M | $9.9M | 0% | Dec 2023 |
|
| MacKay Shields | 9.1M | $8.9M | -8% | Dec 2023 |
|
| Palisade Capital Management | 8.7M | $8.6M | 0% | Dec 2023 |
|
| Man Group | 7.5M | $7.4M | -6% | Dec 2023 |
|
| Royal Bank of Canada | 6.7M | $6.7M | -65% | Dec 2023 |
|
| DLD Asset Management | 5.0M | $4.9M | 100% | Dec 2023 |
|
| Bnp Paribas Arbitrage, Snc | 4.8M | $4.7M | 53% | Dec 2023 |
|
| Citadel Advisors | 4.0M | $3.9M | 100% | Dec 2023 |
|
| Bnp Paribas Investment Partners | 3.5M | $3.4M | 0% | Dec 2023 |
|
| Wells Fargo & Company | 3.5M | $3.4M | -6% | Dec 2023 |
|
| Bank Of Montreal | 3.3M | $3.3M | 94% | Dec 2023 |
|
| Tenor Capital Management | 2.9M | $2.9B | 100% | Dec 2023 |
|
| Jane Street | 2.7M | $2.6M | 100% | Dec 2023 |
|
| Lazard Asset Management | 2.5M | $2.5M | 0% | Dec 2023 |
|
| La Banque Postale Asset Management SA | 2.2M | $2.1M | 23% | Dec 2023 |
|
| Branch Banking & Trust Company | 2.1M | $2.1M | 100% | Dec 2023 |
|
| Nicholas Investments Partners | 1.7M | $1.7M | 0% | Dec 2023 |
|
| Prospector Partners | 1.2M | $1.2M | 9% | Dec 2023 |
|
| Barclays | 1.1M | $1.1M | 100% | Dec 2023 |
|
| Edmond De Rothschild Holding | 1.1M | $1.1M | 0% | Dec 2023 |
|
| Worth Venture Partners | 910k | $899k | 100% | Dec 2023 |
|
| Russell Investments | 621k | $614k | 686% | Dec 2023 |
|
| Kohlberg Kravis Roberts & Co | 225k | $222k | 0% | Dec 2023 |
|
| Calamos Wealth Management | 108k | $107k | -21% | Dec 2023 |
|
| Us Bancorp | 73k | $72k | 0% | Dec 2023 |
|
| Stonegate Investment Group | 50k | $49k | 285% | Mar 2024 |
|
| Balboa Wealth Partners | 47k | $46k | 0% | Dec 2023 |
|
| Argent Trust | 25k | $25k | 0% | Dec 2023 |
|
| SG Americas Securities | 22k | $2.2M | -53% | Dec 2023 |
|
| Raymond James & Associates | 15k | $15k | 0% | Mar 2024 |
|
| Fox Hill Wealth Management | 11k | $11k | 100% | Mar 2024 |
|
| Candriam Luxembourg S.C.A. | 250.00 | $247k | -71% | Dec 2023 |
|
Who sold out of Biomarin Pharma Inc convertible/?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Shenkman Capital Management | Sep 2023 | 17M | $16B |
| SSI Investment Management | Sep 2023 | 8.7M | $8.5M |
| Walleye Trading Advisors | Sep 2023 | 4.8M | $4.7M |
| Arkadios Wealth Advisors | Sep 2023 | 24k | $23k |
| Nomura Holdings | Sep 2023 | 5.4k | $475k |